Future Retirement Success
  • Politics
  • Business
  • Investing
  • Stocks
  • Politics
  • Business
  • Investing
  • Stocks

Future Retirement Success

Politics

Bipartisan bill seeks to stop pharmacy middlemen from driving up drug costs for financial gain

by March 19, 2025
March 19, 2025

A bipartisan group of lawmakers is pushing to reform the incentive structure for Pharmacy Benefit Managers (PBMs), arguing that it drives up patient costs by encouraging them to favor higher-priced drugs while withholding potential savings.

Led by physician and GOP Iowa Rep. Mariannette Miller-Meeks, the group introduced the ‘Delinking Revenue from Unfair Gouging (DRUG) Act’ on Tuesday, requiring that PBMs in the commercial market only charge a flat fee for their services related to a specific prescription drug, versus letting them continue to charge a percentage of the drug price. 

PBMs are third-party intermediaries between insurance companies, drug manufacturers and pharmacies that serve to control drug prices and access. The current incentive structure for PBMs, according to the DRUG Act’s sponsors, encourages them to drive up the list price of drugs to increase profits.    

‘Pharmacy benefit managers (PBMs) have excessive influence over the prices patients pay at the pharmacy counter,’ said Miller-Meeks. ‘Local Iowa pharmacies are closing due to greedy PBM practices, impacting proximity and access to medications for Iowans. The DRUG Act will put downward pressure on prescription drug prices and insurance premiums by removing the incentive for PBMs to drive up the list price of medications.’

According to the Iowa Pharmacy Association, PBMs have been using opaque reimbursement models that often pay back pharmacies less than the list cost of a drug and the services provided to dispense it. 

As a result of these practices, pharmacies in Iowa and across the country have been forced to close, the association said in a January report. Twenty-nine Iowa pharmacies and 2,300 pharmacies nationwide closed their doors in 2024, according to the association.  

While PBMs have played important roles in making drugs more widely available, through decades of mergers and acquisitions, the three largest PBMs now manage nearly 80% of all prescriptions filled in the U.S., according to a 2024 report from the Federal Trade Commission. 

The DRUG Act’s reforms serve to address this anti-competitiveness, which the bill’s sponsors say will also help lower costs.

‘Pharmacy Benefit Managers (PBMs) contribute to high drug costs because they are incentivized to steer patients towards drugs that are more profitable for PBMs, but may be less clinically effective for consumers,’ said Rep. Nannette Barragán, D-Calif., one of the bill’s co-sponsors. ‘This broken system disproportionately harms low-income individuals, seniors, and those with chronic illnesses who rely on life-saving prescriptions to manage their health.’

Rep. Donald Norcross, D-N.J., another co-sponsor of the DRUG Act, said families in his district ‘are crying out for relief from high prescription drug prices.’

‘Americans deserve access to quality health care and affordable prescription drugs,’ Norcross said. ‘The DRUG Act reins in prescription drug prices by removing the incentive for pharmacy benefit managers to drive up costs, increasing transparency and prioritizing patients over profits.’

This post appeared first on FOX NEWS
0
FacebookTwitterGoogle +Pinterest
previous post
Trump doesn’t use autopen for legally binding documents, unlike Biden, White House says
next post
Vance knocks globalization’s ‘cheap labor’ and lauds ‘America’s great industrial comeback’ at AI summit

You may also like

Dems vow to fight ‘tooth and nail’ as...

July 1, 2025

Trump taps Matt Gaetz for attorney general

November 13, 2024

Trump expected to visit Capitol Hill on Wednesday,...

November 12, 2024

Jordan urges supporters to back Scalise for speaker...

October 12, 2023

Israel knows location of Hamas chief Yahya Sinwar,...

January 9, 2024

Tom Cole wins crowded GOP primary to fight...

June 19, 2024

Trump urged to look into US funding of...

February 3, 2025

‘AI powerhouse’: White House encourages Americans to provide...

February 6, 2025

House DOGE subcommittee chair Greene threatens criminal referrals...

February 27, 2025

California to review cases for possible wrongful convictions

February 18, 2023

Dems vow to fight ‘tooth and nail’ as...

July 1, 2025

Trump taps Matt Gaetz for attorney general

November 13, 2024

Trump expected to visit Capitol Hill on Wednesday,...

November 12, 2024

Jordan urges supporters to back Scalise for speaker...

October 12, 2023

Israel knows location of Hamas chief Yahya Sinwar,...

January 9, 2024

Tom Cole wins crowded GOP primary to fight...

June 19, 2024

Trump urged to look into US funding of...

February 3, 2025

‘AI powerhouse’: White House encourages Americans to provide...

February 6, 2025

House DOGE subcommittee chair Greene threatens criminal referrals...

February 27, 2025

California to review cases for possible wrongful convictions

February 18, 2023

    Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • Civil rights group declares ‘state of emergency,’ pointing at Trump admin

      July 17, 2025
    • SCOOP: House fiscal hawks warily accept Senate’s $9B Trump spending cuts package

      July 17, 2025
    • Two Republicans vote against Trump’s $9 billion clawback of foreign aid, NPR funding

      July 17, 2025
    • What Startups Can Learn From Today’s Leading Online Entertainment Platforms

      July 17, 2025
    • RGTI Stock Surged 30% — Is This the Start of a Quantum Comeback?

      July 17, 2025
    • Three Bearish Candle Patterns Every Investor Should Know

      July 17, 2025

    Categories

    • Business (8,509)
    • Investing (2,127)
    • Politics (16,085)
    • Stocks (3,216)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: futureretirementsuccess.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 futureretirementsuccess.com | All Rights Reserved